Bristol-Myers Squibb: Wall Street's Bearish Revisions May Have Overcorrected This Time

Bristol-Myers Squibb reports second-quarter earnings tomorrow before the market opens, with analysts expecting continued momentum from a company that has beaten estimates in four consecutive quarters. The central question is whether BMY can extend its impressive streak of double-digit earnings surprises while navigating a challenging patent cliff and maintaining growth in its key oncology and immunology franchises. With the stock trading near multi-year highs and options pricing a 3.56% move, investors will be watching closely to see if the pharmaceutical giant can justify its recent rally.

Part 1: Earnings Preview

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases, with key franchises in oncology, hematology, immunology, and cardiovascular disease. The company's portfolio includes blockbuster drugs like Eliquis, Opdivo, and Revlimid, though it faces ongoing patent expiration challenges that make pipeline execution critical.

BMY reports Q2 2026 earnings on July 30, 2026, before the market opens. Analysts expect earnings of $1.59 per share, representing +8.90% growth versus the year-ago quarter when the company reported $1.46 per share. The consensus is based on 8 estimates ranging from $1.52 to $1.61. Most recently, BMY reported Q1 2026 earnings of $1.58 per share, beating estimates of $1.44 by 9.72%.

Three key themes define this earnings story:

Patent Cliff Navigation: BMY continues managing the loss of exclusivity for Revlimid, once a revenue powerhouse, while working to offset declines with newer products. Investors will scrutinize whether the company's growth products—including Opdivo combinations, Reblozyl, and Camzyos—are ramping quickly enough to fill the gap.

Pipeline Execution and M&A Integration: Following strategic acquisitions, the market is focused on whether BMY can successfully integrate new assets and advance its pipeline, particularly in oncology and immunology. Any updates on late-stage trials or regulatory milestones could significantly impact sentiment.

Margin Expansion and Cost Management: With revenue growth under pressure from patent expirations, analysts are watching whether BMY can deliver operating leverage through improved margins and disciplined cost control, which would support earnings growth even amid top-line headwinds.

Analyst commentary ahead of the release has been cautiously optimistic. The Zacks Earnings ESP stands at +0.86%, suggesting analysts have grown slightly more bullish on near-term earnings potential. However, estimate revisions over the past 30 days have been modestly negative, with the consensus EPS estimate declining 2.12%, reflecting some uncertainty about the quarter. Multiple analysts note BMY's strong track record of beating estimates, with an average surprise of 9.64% over the past two quarters, which could set the stage for another positive surprise.

Part 2: Historical Earnings Performance

Bristol-Myers Squibb has established an exceptional track record of exceeding analyst expectations, beating consensus estimates in each of the past four quarters. The magnitude of these beats has been substantial, ranging from +9.57% to an impressive +36.45%, with the most dramatic outperformance coming in Q2 2025 when the company reported $1.46 versus the $1.07 estimate.

The pattern shows remarkable consistency in the 9-10% surprise range for the three most recent quarters (Q4 2025, Q3 2025, and Q1 2026), suggesting BMY has developed a reliable cadence of conservative guidance followed by solid execution. The Q2 2025 outlier of +36.45% appears to have been driven by particularly low analyst expectations rather than an operational anomaly, as subsequent quarters returned to the more typical high-single-digit beat pattern.

This consistent outperformance has likely contributed to the recent upward revision in estimates—the current Q2 2026 consensus of $1.59 represents a significant increase from the prior estimate of $1.46. Analysts appear to be adjusting their models to account for BMY's tendency to exceed expectations, though the company's track record suggests there may still be room for another positive surprise tomorrow.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Bristol-Myers Squibb typically reports before market open, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.

BMY exhibits significant volatility around earnings releases, with an average absolute Day 0 move of 5.36% and Day 0 range of 5.19%. The direction has been mixed but generally positive, with five of the past eight releases showing gains on Day 0. The most dramatic move came in July 2024 with an +11.44% surge, while the largest decline was -5.81% in July 2025.

Day +1 follow-through has been more muted, averaging 2.41% in absolute terms with a 3.29% range, suggesting most of the price discovery happens in the immediate reaction. Notably, the most recent earnings release in April 2026 showed a strong +5.21% Day 0 gain followed by a -3.91% Day +1 reversal, indicating profit-taking after the initial enthusiasm. This pattern of strong initial reactions with mixed follow-through suggests traders should be prepared for significant volatility in tomorrow's session, with the potential for substantial moves in either direction depending on whether BMY can deliver another beat and provide encouraging forward guidance.

Part 2.2: Options Market Expected Move

The options market is pricing a 3.56% expected move for this week's expiration, which is notably below BMY's average historical Day 0 move of 5.36% around earnings. This suggests options traders may be underestimating potential volatility, particularly given BMY's track record of significant post-earnings swings and four consecutive quarters of earnings beats that have driven substantial price reactions.

Part 3: What Analysts Are Saying

Analyst sentiment on Bristol-Myers Squibb reflects cautious optimism, with a consensus rating of 3.63 (between Hold and Buy) based on 30 analysts. The breakdown shows 10 Strong Buys, 1 Moderate Buy, 18 Holds, 0 Moderate Sells, and 1 Strong Sell, indicating a divided Street with more bulls than bears but significant fence-sitting among the analyst community.

The average price target of $62.77 sits essentially at the current price of $63.10, implying minimal upside of approximately -0.5% from current levels. However, the wide range of targets—from a low of $40.00 to a high of $75.00—reveals substantial disagreement about BMY's valuation and prospects. The high-end target suggests potential upside of nearly 19% for bulls who believe in the company's pipeline and ability to navigate patent expirations.

Sentiment has improved over the past month, with the average recommendation ticking slightly more positive from 3.61 to 3.63. This modest improvement, combined with the stock's recent strength, suggests analysts are gaining confidence in BMY's execution, though the heavy Hold weighting indicates many remain on the sidelines waiting for more evidence of sustainable growth beyond the patent cliff. The consensus appears to be that BMY is fairly valued at current levels, with the upcoming earnings report serving as a potential catalyst to either validate the recent rally or prompt a reassessment of the growth trajectory.

Part 4: Technical Picture

Bristol-Myers Squibb enters earnings with strong technical momentum, as the Barchart Technical Opinion currently stands at 72% Buy, unchanged from last week but significantly improved from 48% Buy a month ago. This strengthening signal reflects the stock's sustained rally above all key moving averages.

Timeframe Analysis:

• Short-term (100% Buy): Maximum bullish signal indicates powerful near-term momentum heading into the earnings release
• Medium-term (Hold): Neutral reading suggests some consolidation may be needed after the recent advance
• Long-term (100% Buy): Strong buy signal confirms the broader uptrend remains intact despite patent cliff concerns

Trend Characteristics: The trend is rated as Good strength and Strengthening direction, indicating BMY has established a solid uptrend with improving momentum that provides a supportive technical backdrop for tomorrow's earnings.

The stock is trading above all major moving averages, with the current price of $63.10 well above the 200-day moving average at $55.35, the 50-day at $57.83, and even the short-term 5-day at $62.57. This alignment—with all moving averages in proper ascending order—is a classic bullish configuration that suggests institutional accumulation and strong underlying demand.

Key resistance may emerge near the $65 level implied by the options expected move, while support appears solid in the $60-61 zone where the 10-day and 20-day moving averages converge. The technical setup is decidedly supportive heading into earnings, with momentum indicators, moving average alignment, and the Barchart Opinion all pointing to strength. However, the stock's position near recent highs means BMY will likely need to deliver a strong beat and raise guidance to justify further upside, as any disappointment could trigger profit-taking from the recent rally. The combination of bullish technicals and high expectations creates a classic "show me" setup where execution matters more than ever.